Year in Review: New Guidelines, Inclisiran, Dapagliflozin Impact CVD Prevention in 2019
Headlines have led to outside-the-box thinking as well as a more global perspective in preventing CV disease and events.
Headlines have led to outside-the-box thinking as well as a more global perspective in preventing CV disease and events.
Sign Up for Our Newsletter Get the latest news and updates from TCTMD. Forgot Your Password? Enter the email you used to register to reset…
The advantage of apixaban was consistent across a variety of subgroups and confirms earlier observations.
At this early age, metabolism is already dysregulated and lifestyle changes are warranted to prevent future disease.
Trialists should focus less on physician-defined outcomes and more on what matters to patients, Mario Gaudino says.
Bernard Prendergast and Jordan Strom discuss the evolution of AS referral and how earlier treatment impacts patient outcomes.
Philippe Généreux, Brad Oldemeyer, and Jennifer Daniel share their experiences treating asymptomatic aortic stenosis patients in the EARLY TAVR trial.
The early impact of gestational diabetes, hypertensive disorders of pregnancy, and obesity appears to grow as kids age.
Use of embolic protection declined—but didn’t disappear—in the US after the trial’s findings. Marwan Saad, MD, PhD, explains the data.
When weight loss is equal, though, the GLP-1s seem to provide larger benefits. Researchers say prospective studies are needed.
The findings highlight the importance of rheumatology, cardiology, and primary care working together to intervene early.